Onychomycosis (Tinea Unguium) (Infectious Disease) - Drugs in Development, 2021

March 2021 | 81 pages | ID: O85D584EA6EFEN
Global Markets Direct

Abstracts

Onychomycosis (Tinea Unguium) (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis - Drugs in Development, 2021, provides an overview of the Onychomycosis (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Onychomycosis - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Onychomycosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 7, 1, 4, 1 and 2 respectively.

Onychomycosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Onychomycosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Onychomycosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Onychomycosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Onychomycosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) - Overview
Onychomycosis (Tinea Unguium) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Onychomycosis (Tinea Unguium) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
Acea Biotech Inc
Almirall SA
ASCIL Biopharm
Blueberry Therapeutics Ltd
CSA Biotechnologies LLC
DermBiont Inc
Exodos Life Sciences Limited Partnership
Hallux Inc
Hexima Ltd
Kaken Pharmaceutical Co Ltd
Moberg Pharma AB
Mycovia Pharmaceuticals Inc
NAL Pharmaceuticals Ltd
Novabiotics Ltd
Photonamic GmbH & Co KG
SaNOtize Research and Development Corp
Onychomycosis (Tinea Unguium) - Drug Profiles
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-0305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELS-160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HXP-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NORS-0791 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onymed - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oteseconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-3058 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Disrupt Cell Membrane for Onychomycosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Onychomycosis (Tinea Unguium) - Dormant Projects
Onychomycosis (Tinea Unguium) - Discontinued Products
Onychomycosis (Tinea Unguium) - Product Development Milestones
Featured News & Press Releases
Jan 07, 2021: Updated timeline to phase IIb results
Oct 14, 2020: Moberg Pharma intends to submit a registration application in Europe in 2021
Jun 25, 2020: Moberg Pharma meets primary endpoint in the European phase 3 study
Mar 23, 2020: All patients in the European MOB-015 Phase 3 study have completed their last visit
Jan 28, 2020: Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603
Jan 22, 2020: Expert evaluation clarifies phase 3 results and provides strong support for MOB-015
Dec 12, 2019: Moberg Pharma comments on the results of the North American Phase 3 study with MOB-015
Dec 09, 2019: Moberg Pharma meets primary endpoint for MOB-015 in a phase 3 study for the treatment of Onychomycosis
Apr 18, 2019: UK-Based Nanomedicine firm set plans to initiate a large phase II efficacy study in 2019
Mar 22, 2019: Moberg Pharma completes enrollment for MOB-015 phase 3 study in Europe
Dec 18, 2018: Almirall announces that the Phase III trial of P-3058 for onychomycosis achieved primary endpoint
Nov 23, 2018: Blueberry reports positive results from Phase I/II BB2603 trial
Nov 23, 2018: Moberg Pharma: Patent granted for MOB-015 in China
Sep 11, 2018: Moberg Pharma has completed enrollment to Phase 3 study for MOB-015 in North America
Nov 21, 2017: Hexima Receives Approval to Conduct a Phase 1/2a Study for Fungal Nail Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Onychomycosis (Tinea Unguium), 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Onychomycosis (Tinea Unguium) - Pipeline by Acea Biotech Inc, 2021
Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, 2021
Onychomycosis (Tinea Unguium) - Pipeline by ASCIL Biopharm, 2021
Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, 2021
Onychomycosis (Tinea Unguium) - Pipeline by CSA Biotechnologies LLC, 2021
Onychomycosis (Tinea Unguium) - Pipeline by DermBiont Inc, 2021
Onychomycosis (Tinea Unguium) - Pipeline by Exodos Life Sciences Limited Partnership, 2021
Onychomycosis (Tinea Unguium) - Pipeline by Hallux Inc, 2021
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, 2021
Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co Ltd, 2021
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, 2021
Onychomycosis (Tinea Unguium) - Pipeline by Mycovia Pharmaceuticals Inc, 2021
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, 2021
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, 2021
Onychomycosis (Tinea Unguium) - Pipeline by Photonamic GmbH & Co KG, 2021
Onychomycosis (Tinea Unguium) - Pipeline by SaNOtize Research and Development Corp, 2021
Onychomycosis (Tinea Unguium) - Dormant Projects, 2021
Onychomycosis (Tinea Unguium) - Dormant Projects, 2021 (Contd..1)
Onychomycosis (Tinea Unguium) - Dormant Projects, 2021 (Contd..2)
Onychomycosis (Tinea Unguium) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Onychomycosis (Tinea Unguium), 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021